Zak Mir takes a charting look at some of the most followed small caps. Today’s selection includes AfriTin, Arrow Exploration, Alkemy, Angus, Aminex, Angle, Blue Star, Cordel, Galantas, Hurricane, Minoan,

Zak Mir takes a charting look at some of the most followed small caps. Today’s selection includes AfriTin, Arrow Exploration, Alkemy, Angus, Aminex, Angle, Blue Star, Cordel, Galantas, Hurricane, Minoan,
Although the news was widely distributed yesterday, presumably to give shareholders an extra bad night’s sleep,
Zak Mir takes a technical perspective on some of the most followed small caps on the London market. Today’s selection includes Blue, Challenger, Eve, Feedback, Hemo, Live, Midatech, MyHealth, Nanosynth,
Zak Mir takes a technical look at some of the most followed small caps on the London market – as well as the FTSE 100 index in the wake of
Zak Mir takes a technical perspective on some of the most followed stocks of the day. Today’s selection includes Avacta, BT, Braveheart, EQTEC, i3 Energy, MyHealthChecked, Novacyt, Nanosynth, Rockfire, Sourcebio.
Zak Mir takes a technical perspective on some of the most followed small caps via the charts of the FTSE 100 and Bitcoin. Today’s stocks include Agronomics, Dev Clever, EQTEC,
Zak Mir takes a technical perspective on some of the most followed small caps on the London market. Today’s selection includes Braveheart, Genedrive, MyHealthChecked, Novacyt, Nanosynth, Scancell, Sareum, Synairgen and
Zak Mir takes a technical perspective on some of the most followed small caps in London. Today’s selection includes Beowulf Mining, Bezant Resources, Chill Brands Group, Eurasia Mining, Gunsynd, Myhealthchecked,
Zak Mir takes a technical analysis perspective on some of the most followed small caps on the London market. Today’s selection includes Arrow, Gunsynd, Galantus, Itaconix, MyHealthChecked, Power Metal, Pembridge,
The AIM All-Share fell 0.7% over the week in the small-cap market. This was lower than the FTSE 100 which grew 1.3 percent.
There was two for the price of one at pharma services group Open Orphan (ORPH), not only its hVIVO subsidiary signing a £5.7m contract with a specialist biotechnology company developing